Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
AEIS just put up 26% Q1 revenue growth, more than doubled Data Center Computing revenue, crossed a 40% non-GAAP gross-margin milestone, and priced $1.0 billion of 0% convertible notes. The upside is real; so are the customer, working-capital, and dilution ques
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Aehr Test just printed a $37.2 million bookings quarter tied to AI processors, silicon photonics, and hyperscale data-center infrastructure. The harder part is still ahead: turning that order rebound into revenue, margin recovery, and per-share value after a w
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenACM Research has 34% Q1 revenue growth, 54% shipment growth, a billion-dollar cash stack, and a widening semiconductor equipment portfolio. The decision point is whether a China-centered operating model can turn that momentum into global, repeatable, per-share
OpenAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
OpenTag facets appear after tag usage counts are rebuilt.